Key result
11-day ECG patch detects ~250% more drug-refractory AF or AT than 24-h Holter.
Why the study?
Accurate assessment of antiarrhythmic drug response in atrial fibrillation is crucial for rhythm control, but the effectiveness of extended adhesive ECG patch monitoring for detecting drug-refractory paroxysmal atrial fibrillation needed evaluation.
Does 11-day adhesive ECG patch monitoring improve the detection rate of drug-refractory AF or AT compared to a 24-h Holter test in patients with paroxysmal AF receiving AAD therapy?
Observational (n=59)
Does 11-day adhesive ECG patch monitoring improve the detection rate of drug-refractory AF or AT compared to a 24-h Holter test in patients with paroxysmal AF receiving AAD therapy?
Absolute Event Rate: 47.5% vs 13.6%
p-value: p=<0.001
Extended 11-day ECG patch monitoring significantly increases the detection of drug-refractory AF compared to standard 24-hour Holter monitoring, leading to actionable changes in clinical management.
Extended patch monitoring may increase drug-refractory AF/AT detection; leaves open impact on outcomes and practice change.
Accurate assessment of the response to the antiarrhythmic drug (AAD) in atrial fibrillation (AF) is crucial to achieve adequate rhythm control. We evaluated the effectiveness of extended cardiac monitoring using an adhesive ECG patch in the detection of drug-refractory paroxysmal AF. Patients diagnosed with paroxysmal AF and receiving AAD therapy were enrolled. The subjects simultaneously underwent 11-day adhesive ECG patch monitoring and a 24-h Holter test. The primary study outcome was a detection rate of drug-refractory AF or atrial tachycardia (AT) lasting ≥30 s. A total of 59 patients were enrolled and completed the study examinations. AF or AT was detected in 28 (47.5%) patients by an 11-day ECG patch monitor and in 8 (13.6%) patients by a 24-h Holter test (p < 0.001). The 11-day ECG patch monitor identified an additional 20 patients (33.8%) with drug-refractory AF not detected by the 24-h Holter, and as a result, the treatment plan was changed in 11 patients (10 catheter ablations, one medication change). In conclusion, extended cardiac rhythm monitoring using an adhesive ECG patch in patients with paroxysmal AF under AAD therapy led to over a threefold higher detection of drug-refractory AF episodes, compared to the 24-h Holter test.
No takes yet. Share an insight, caveat, or question.
Kim et al. (2023) conducted an observational in Paroxysmal Atrial Fibrillation (n=59). 11-day adhesive ECG patch monitoring vs. 24-h Holter test was evaluated on Detection rate of drug-refractory AF or atrial tachycardia (AT) lasting ≥30 s (p=<0.001). Extended cardiac monitoring using an 11-day adhesive ECG patch detected drug-refractory AF or AT in 47.5% of patients compared to 13.6% with a 24-h Holter test (p < 0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: